To investigate whether RBP2 was critical in CML progression, we measured RBP2 mRNA and protein levels in bone-marrow samples from patients with newly diagnosed CML-CP or CML-BP. This evidence concerns the gene RBP2 and chronic myelogenous leukemia, BCR-ABL1 positive.